Posted by Michael Wonder on 16 Nov 2020
Lupin announces FDA filing acceptance of supplemental new drug application for Solosec (secnidazole) for the treatment of trichomoniasis
16 November 2020 - Lupin Pharmaceuticals announced today that the U.S. FDA has accepted their supplemental new drug application for Solosec (secnidazole) for the treatment of trichomoniasis in adults and adolescents.
The FDA has assigned a Prescription Drug User Fee Act target date of 30 June 2021.
